Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 16,116 shares at $17.98 ($290K) on 2023-07-10, disclosed to the SEC on 2023-07-12.
Scheduled sale ($290k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.98 | 6,116 | $110K | 37.9% |
| 2 | $17.98 | 6,116 | $110K | 37.9% |
| 3 | $18.00 | 3,884 | $70K | 24.1% |
| Total | $17.98 avg | 16,116 | $290K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |